Saturday 17 October 2026
Export DYAI’s income statement to Excel — free account
Dyadic International Inc.
DYAI Healthcare Biotechnology
Dyadic International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.1 million, down 11.6% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS was flat, free cash flow fell 1,298.5% and total debt was flat, each against the same quarter a year earlier.
0.41
0.01
−2.38%
Follow DYAI
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 | 3 | 4 | 4 | 4 | 4 | 2 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | 31.30 | 36.48 | 51.62 | 52.26 | 20.64 | (0.80) | (3.89) | (8.73) | (12.37) |
P/S ratio |
0.00 | 63.08 | 40.39 | 83.21 | 92.26 | 52.35 | 13.36 | 15.80 | 14.68 | 9.92 |
Altman Z″-Score (non-manufacturers) |
— | 71.82 | 55.15 | 24.41 | 16.78 | (2.08) | (12.77) | (31.29) | (27.03) | (31.25) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | (2.39) | (2.80) | (3.54) | (3.36) | (3.27) | (2.54) | (4.48) | 1.00 |
P/Operating CF |
0.00 | (28.31) | (42.57) | (99.85) | (114.84) | (47.75) | (23.27) | (49.59) | (73.67) | (17.32) |
P/B ratio |
0.00 | 0.96 | 1.23 | 3.90 | 5.20 | 6.84 | 3.53 | 7.79 | 20.77 | 24.88 |
Price to Tangible BV |
0.00 | 0.96 | 1.23 | 3.90 | 5.20 | 6.84 | 3.53 | 7.79 | 20.77 | 24.88 |
EV/Sales |
(8.35) | 0.25 | 8.57 | 62.85 | 74.10 | 43.92 | 9.04 | 13.33 | 13.45 | 8.78 |
EV/EBITDA |
0.00 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | (0.16) | (2.52) | (18.27) | (18.06) | (9.36) | (3.28) | (5.74) | (11.83) | (4.76) |
EV/FCF |
0.00 | (0.15) | (2.46) | (17.93) | (17.76) | (9.27) | (3.23) | (5.65) | (11.51) | (4.67) |
Quick Ratio |
56.81 | 63.01 | 49.81 | 22.27 | 18.14 | 8.07 | 5.32 | 3.44 | 3.89 | 2.62 |
Current Ratio |
57.05 | 64.53 | 50.32 | 22.44 | 18.32 | 8.22 | 5.48 | 3.58 | 4.01 | 2.68 |
Net Debt/EBITDA |
(94.95) | 7.57 | 5.96 | 3.77 | 3.00 | 1.41 | 1.25 | 0.88 | 0.73 | 0.49 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 50.12% | 50.53% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.01 | 4.08 |
Asset Turnover |
0.00 | 0.03 | 0.03 | 0.04 | 0.05 | 0.09 | 0.17 | 0.26 | 0.39 | 0.31 |
Operating CF/Net income |
1.67 | 0.79 | 0.77 | 0.70 | 0.71 | 0.86 | 0.83 | 0.99 | 0.68 | 0.77 |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
1.22 | (13.08) | (8.49) | (9.42) | (22.43) | (284.86) | (56.35) | — | (13.79) | (15.78) |
| (12.14%) | (3.97%) | (12.32%) | (21.22%) | (29.00%) | (55.81%) | (66.05%) | (80.11%) | (139.16%) | (397.80%) | |
| 0.00% | (8.42%) | (12.10%) | (20.58%) | (27.62%) | (50.89%) | (55.61%) | (61.97%) | (64.01%) | (74.11%) | |
ROIC |
26.74% | 20.70% | (380.11%) | (353.37%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(6.37%) | (4.37%) | (13.58%) | (24.40%) | (33.12%) | (70.83%) | (88.72%) | (116.85%) | (78.72%) | (118.60%) |
Average Days of Receivables |
665.62 | 366.20 | 315.53 | 247.19 | 92.60 | 56.52 | 48.37 | 59.96 | 27.29 | 132.92 |
Research and Development Expense of Revenue |
149.34% | 290.49% | 256.06% | 235.34% | 241.47% | 349.13% | 153.62% | 113.75% | 58.49% | 69.72% |
Selling, General and Administrative Expense of Revenue |
659.21% | 663.29% | 349.11% | 328.35% | 379.85% | 278.63% | 219.14% | 200.67% | 175.51% | 186.44% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 84.84% | 36.06% | 69.66% | 103.12% | 74.22% | 64.46% | 42.92% | 32.22% | 30.10% |
Graham Net Nets |
0.00 | 1.02 | 0.80 | 0.24 | 0.19 | 0.14 | 0.28 | 0.13 | 0.05 | 0.04 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(5.70%) | (5.00%) | (10.91%) | (5.98%) | (6.34%) | (10.39%) | (24.64%) | (15.09%) | (11.25%) | (26.60%) |
Free Cash Flow Yield |
0.00% | (2.72%) | (8.64%) | (4.21%) | (4.52%) | (9.05%) | (20.94%) | (14.93%) | (7.96%) | (18.96%) |
Revenue per Share |
0.02 | 0.03 | 0.05 | 0.06 | 0.06 | 0.09 | 0.10 | 0.10 | 0.12 | 0.09 |
Operating CF per Share |
(0.17) | (0.06) | (0.16) | (0.21) | (0.24) | (0.41) | (0.28) | (0.23) | (0.14) | (0.17) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.17) | (0.06) | (0.16) | (0.21) | (0.24) | (0.41) | (0.28) | (0.23) | (0.14) | (0.17) |
Cash per Share |
1.54 | 1.65 | 1.49 | 1.27 | 1.06 | 0.73 | 0.45 | 0.25 | 0.32 | 0.26 |
Shareholders Equity per Share |
1.58 | 1.73 | 1.53 | 1.33 | 1.04 | 0.66 | 0.39 | 0.20 | 0.08 | 0.04 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.58 | 1.73 | 1.53 | 1.33 | 1.04 | 0.66 | 0.39 | 0.20 | 0.08 | 0.04 |
Free Cash Flow |
(6.04) | (1.69) | (4.41) | (5.78) | (6.57) | (11.28) | (8.08) | (6.73) | (3.97) | (5.70) |
Working Capital |
56.62 | 48.85 | 41.90 | 34.05 | 28.16 | 18.45 | 10.97 | 5.82 | 7.38 | 6.21 |
Net Current Asset Value |
56.62 | 48.85 | 41.90 | 34.05 | 28.16 | 18.10 | 10.80 | 5.73 | 2.37 | 1.18 |
EV/EBIT |
0.00 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 63.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
(5.29%) | (1.73%) | (5.27%) | (8.25%) | (11.43%) | (29.18%) | (34.07%) | (51.19%) | (23.79%) | (38.50%) |
Accounts Receivable Turnover |
0.51 | 0.82 | 1.38 | 1.49 | 2.07 | 6.17 | 7.71 | 6.71 | 9.48 | 4.46 |
Accounts Payable Turnover |
0.53 | 1.70 | 2.48 | 2.33 | 1.46 | 1.52 | 1.50 | 2.04 | 2.10 | 3.48 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
197.35 | 279.20 | 109.82 | 235.90 | 259.51 | 290.59 | 219.41 | 121.26 | 147.36 | 134.05 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
1.17 | 0.92 | 0.94 | 1.13 | 0.77 | 0.39 | 0.38 | 0.43 | 0.37 | 0.69 |
Average Payables |
0.98 | 0.40 | 0.41 | 0.63 | 0.98 | 1.28 | 1.41 | 0.97 | 0.57 | 0.67 |
Average Assets |
0.00 | 25.37 | 47.02 | 40.38 | 33.76 | 25.69 | 17.51 | 10.97 | 9.07 | 9.94 |
Average Common Equity |
29.74 | 53.83 | 46.21 | 39.16 | 32.16 | 23.42 | 14.74 | 8.48 | 4.17 | 1.85 |
Columns are period end dates